viewReNeuron Group PLC

ReNeuron wins Breakthrough of the Year Award

/**/ h1{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h2{margin:0cm;margin-bottom:.0001pt;font-size:16.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h4{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:16.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h5{margin:0cm;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h6{margin:0cm;margin-bottom:.0001pt;text-align:right;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: purple } .bc{size:595.3pt 841.9pt;margin:49.65pt 85.0pt 49.65pt 90.0pt;}div.bc{}h1.ch{text-indent:117.0pt}span.ci{font-weight:normal}table.ck{width:517.4pt;margin-left:-33.75pt;border-collapse:collapse}td.cf{width:171.8pt;padding:0cm 5.4pt 0cm 5.4pt}span.cg{font-family:"Calibri","sans-serif"}td.cc{width:324.0pt;padding:0cm 5.4pt 0cm 5.4pt}h3.ce{text-align: right}h3.cd{margin-right: 50.95pt; text-align: center} h1.ca{text-align: center}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;}p.cl{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align: center}p.cm{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: center}span.bx{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.cn{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;margin-top:0cm;margin-right:-19.15pt;margin-bottom: 0cm;margin-left:-21.3pt;margin-bottom:.0001pt;text-align:justify;text-justify: inter-ideograph}p.co{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;font-weight: bold; margin-bottom: 0cm; margin-left: -21.3pt; margin-right: -19.15pt; margin-top: 0cm; text-align: justify; text-justify: inter-ideograph}p.cp{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; margin-bottom: 0cm; margin-left: -21.3pt; margin-right: -19.15pt; margin-top: 0cm; text-align: center}span.bu{font-family:"Calibri","sans-serif";color:black}table.cq{margin-left:-10.8pt;border-collapse:collapse} tr.bp{height:28.75pt}td.br{width:299.4pt;padding:0cm 5.4pt 0cm 5.4pt; height:28.75pt}p.cr{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;font-weight: bold}td.bq{width:138.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:28.75pt}p.aq,li.aq,div.aq{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;}tr.bn{height:6.0pt}td.bo{width:448.2pt;padding:0cm 5.4pt 0cm 5.4pt; height:6.0pt}td.bm{width:299.4pt;padding:0cm 5.4pt 0cm 5.4pt; height:6.0pt}td.bl{width:138.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:6.0pt}tr.bi{height:20.6pt} td.bk{width:299.4pt;padding:0cm 5.4pt 0cm 5.4pt; height:20.6pt}td.bj{width:138.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:20.6pt}tr.bf{height:12.65pt}td.bh{width:299.4pt;padding:0cm 5.4pt 0cm 5.4pt; height:12.65pt}td.bg{width:138.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:12.65pt}p.cs{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;text-align:justify;text-justify:inter-ideograph}p.ct{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; margin-bottom: 0cm; margin-left: -21.3pt; margin-right: -19.15pt; margin-top: 0cm; text-align: justify; text-justify: inter-ideograph} /**/
RNS Number : 3382C
ReNeuron Group plc
14 June 2019







14 June 2019





                                                              AIM: RENE



RNS Reach


ReNeuron Group plc

("ReNeuron" or the "Company")


ReNeuron wins Breakthrough of the Year Award


ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is delighted to announce that it has won the 'Breakthrough of the Year' award at last night's 2019 European Mediscience Awards in London.


This award underlines the strong clinical development and commercial progress ReNeuron has made over the past year.  This includes positive data from the ongoing Phase 1/2a clinical trial in Retinitis Pigmentosa and the signing of an exclusive licence agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. for the development, manufacture and commercialisation of ReNeuron's CTX and hRPC cell therapy programmes in the People's Republic of China.


Olav Hellebø, Chief Executive Officer of ReNeuron, commented:


"We are delighted to have been awarded the Breakthrough of the Year award at the 2019 European Mediscience Awards. We are greatly encouraged by the progress we have made with our cell therapy clinical development programmes for retinitis pigmentosa and stroke disability over the past year and look forward to continuing to advance our clinical and business development activities in the months ahead."


The European Mediscience Awards is one of the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe.  It celebrates the best in the sector and highlights the achievements of individuals and companies operating within it.









+44 (0) 20 3819 8400

Olav Hellebø, Chief Executive Officer

Michael Hunt, Chief Financial Officer


Buchanan (UK Media/Investor Relations)


+44 (0) 20 7466 5000

Mark Court, Sophie Wills, Tilly Abraham


Argot Partners (US Media/Investor Relations)

Stephanie Marks, Claudia Styslinger


+1 212 600 1902


Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Jonathan Senior, Stewart Wallace, Ben Maddison


+44 (0) 20 7710 7600



N+1 Singer (Joint Broker)

Aubrey Powell, Mark Taylor


+44 (0) 20 7496 3000



About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off-the-shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: ReNeuron Group PLC

Price: 126

Market: LSE
Market Cap: £40.11 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Investor Update: Punchy read-through valuation for ADM Energy's Nigerian oil...

Headlines from the Proactive UK newsroom. ADM Energy (LON:ADME) has had a punchy read-through valuation placed on its 5% stake in its field, offshore Nigeria. Petronor has acquired a 12.2% economic interest for US$10mln with a further US$25mln based on future gas production. Reneuron...

on 23/10/19